IP Library Granted Patent US 8,173,107
Granted Patent B2
US 8,173,107 · App. 12/413,339 · Granted May 8, 2012

Delivery of antipsychotics through an inhalation route

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,173,107
App. No.
12/413,339
Granted
May 8, 2012
Kind
B2
Abstract

The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a method aspect of the present invention, an antipsychotic is delivered to a patient through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises an antipsychotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% antipsychotic drug degradation products. In a kit aspect of the present invention, a kit for delivering an antipsychotic through an inhalation route is provided which comprises: a) a thin coating of an antipsychotic composition and b) a device for dispensing said thin coating as a condensation aerosol.

Claims (8)

1. An aerosol for delivery of loxapine by inhalation comprising condensation particles having an MMAD of 0.2 to 5 microns and a high particle concentration of the condensation particles.

2. The aerosol of claim 1 , wherein the aerosol is at least 90% free of additional compounds.

3. The aerosol of claim 1 , wherein the condensation particles have and MMAD of 1-3 microns.

4. The aerosol of claim 1 , wherein the high particle concentration of the condensation particles is about 10 9 particles/ml.

5. An aerosol for delivery of loxapine by inhalation comprising condensation particles having an MMAD of 0.2 to 5 microns and a particle density greater than 10 6 particles/ml.

6. The aerosol of claim 5 , wherein the aerosol is at least 90% free of additional compounds.

7. The aerosol of claim 5 , wherein the condensation particles have an MMAD of 1-3 microns.

8. The aerosol of claim 5 , wherein the aerosol has a particle density of about 10 9 particles/ml.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2009
From: RABINOWITZ, JOSHUA D.; ZAFFARONI, ALEJANDRO C.
To: ALEXZA MOLECULAR DELIVERY CORPORATION
Reel/Frame 022477/0215 →
CHANGE OF NAME Recorded Mar 31, 2009
From: ALEXZA MOLECULAR DELIVERY CORPORATION
To: ALEXZA PHARMACEUTICALS, INC.
Reel/Frame 022477/0408 →